7 active not recruiting, 6 completed, 6 recruiting, 6 terminated. 32 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 32 | Active not recruiting 7, Completed 6, Recruiting 6, Terminated 6, Withdrawn 5, Unknown 2 |
| Phase 1 | 6 | Active not recruiting 2, Recruiting 2, Completed 1, Terminated 1 |
Follow Cutaneous Squamous Cell Carcinoma: new trials by email Literature Review of Cutaneous Squamous Cell Carcinoma trials Research Report on Cutaneous Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IDP-001 in Advanced or Metastatic Solid Tumors IDP-001 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | InduPro, Inc. | 132 | 2026-07-08 | 2026-09-03 |
| TIL Therapy in cSCC and MCC LN-145, Cyclophosphamide, Fludarabine - Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Karam Khaddour, MD, MS | 14 | 2026-02-10 | 2026-02-13 |
| Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU - Immunotherapy, Cutaneous Squamous Cell Carcinoma | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-01-01 | 2025-05-07 | |
| Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU - Cutaneous Squamous Cell Carcinoma, Actinic Keratoses | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-01-01 | 2025-05-07 | |
| Towards Cure Via Only Ultra-short ICB in CSCC Nivolumab, Ipilumimab - Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer | Phase 2 | Recruiting | The Netherlands Cancer Institute | 41 | 2025-05-14 | 2025-05-29 |
| Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma Tranexamic acid - Cutaneous Squamous Cell Carcinoma | Phase 2 | Withdrawn | University of Florida | 2025-05-01 | 2025-05-02 | |
| Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma Ivonescimab - Cutaneous Squamous Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 24 | 2024-12-02 | 2026-06-11 |
| Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) cemiplimab, fianlimab - Cutaneous Squamous Cell Carcinoma | Phase 2 | Withdrawn | Regeneron Pharmaceuticals | 2024-11-14 | 2024-07-26 | |
| Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) Aminolevulinic acid hydrochloride 10% topical gel with Red Light - Cutaneous Squamous Cell Carcinoma | Phase 2 | Unknown | The Center for Clinical and Cosmetic Research | 20 | 2024-08-14 | 2024-08-29 |
| Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination - Cutaneous Squamous Cell Carcinoma | Phase 2 | Recruiting | Melanoma Institute Australia | 20 | 2024-06-21 | 2026-07-08 |
| A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma INCB099280 - Cutaneous Squamous Cell Carcinoma | Phase 2 | Terminated | Incyte Corporation | 63 | 2023-10-09 | 2026-10-20 |
| Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) favezelimab/pembrolizumab, pembrolizumab, lenvatinib - Solid Tumor, Cutaneous Squamous Cell Carcinoma | Phase 2 | Completed | Merck Sharp & Dohme LLC | 163 | 2023-09-29 | 2026-03-19 |
| Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC) Microneedle Array Doxorubicin (MNA-D) - Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Falo, Louis, MD | 48 | 2023-09-13 | 2026-04-09 |
| Deep sequencIng in Cutaneous Squamous CEll caRciNomas Cemiplimab - Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 11 | 2023-05-26 | 2026-09-21 |
| Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas IMT-009, Fruquintinib - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Immunitas Therapeutics | 67 | 2022-11-28 | 2025-10-16 |
| A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Cemiplimab, Radiotherapy - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 34 | 2022-10-06 | 2026-05-15 |
| Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders Fecal Microbiota Transplant (FMT) - Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Oslo University Hospital | 20 | 2022-06-28 | 2025-07-03 |
| A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Nanrilkefusp Alfa, Pembrolizumab - Non-Small Cell Lung Cancer, Colorectal Cancer | Phase 2 | Terminated | SOTIO Biotech AG | 166 | 2022-06-21 | 2025-11-17 |
| The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) HLX07 - Cutaneous Squamous Cell Carcinoma | Phase 2 | Unknown | Shanghai Henlius Biotech | 20 | 2022-06-15 | 2022-06-21 |
| Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma Imgatuzumab - Cutaneous Squamous Cell Carcinoma | Phase 2 | Withdrawn | Pega-One S.A.S. | 2021-12-16 | 2022-09-13 |
Showing 20 of 32. Sign in to see all of them.
Carcinoma, Squamous Cell (6) · Skin Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (6) · Neoplasm Metastasis (5) · Carcinoma, Merkel Cell (4) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (3) · Melanoma (3) · Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Carcinoma (2) · Carcinoma, Basal Cell (2) · Carcinoma, Renal Cell (2) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2)
Neoplasms (15) · Neoplasms by Histologic Type (15) · Neoplasms, Glandular and Epithelial (15) · Neoplasms by Site (14) · Carcinoma (13) · Skin Diseases (10) · Skin and Connective Tissue Diseases (10) · Adenocarcinoma (6) · Neoplasms, Squamous Cell (6) · Pathological Conditions, Signs and Symptoms (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Carcinoma, Squamous Cell (5) · DNA Virus Infections (5) · Head and Neck Neoplasms (5)
cemiplimab (8) · pembrolizumab (4) · Nivolumab (3) · Fluorouracil (2) · Immunotherapy (2) · Interleukin-2 (2) · Petrolatum (2) · atezolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Aminolevulinic Acid (1) · Cetuximab (1) · Cyclophosphamide (1) · Doxorubicin (1) · Everolimus (1)
Regeneron Pharmaceuticals (3) · Massachusetts General Hospital (2) · The Netherlands Cancer Institute (2) · Dana-Farber Cancer Institute (1) · Falo, Louis, MD (1) · Fondazione Melanoma Onlus (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Icahn School of Medicine at Mount Sinai (1) · Immunitas Therapeutics (1) · Incyte Corporation (1) · InduPro, Inc. (1) · Karam Khaddour, MD, MS (1) · M.D. Anderson Cancer Center (1) · Medicenna Therapeutics, Inc. (1) · Melanoma Institute Australia (1)
United States (21) · Australia (8) · Canada (4) · France (4) · Italy (4) · Spain (4) · Germany (3) · Netherlands (3) · Hungary (2) · Poland (2) · South Korea (2) · Turkey (Türkiye) (2) · Belgium (1) · Brazil (1) · Bulgaria (1)
Shadmehr Demehri, MD/PHD (2) · Annette M Lim, MBBS, FRACP, PhD (1) · Arash Yavari, MBBS (1) · Assuntina Sacco, M.D. (1) · Aung Naing, MD (1) · Bently Doonan, MD, MS (1) · Brian Gastman, MD (1) · Christine H Chung, MD (1) · Christopher Barker, MD (1) · Glenn J Hanna, MD (1) · Ines Da Silva (1) · Jeannie Hou, MD (1) · Jon Amund Kyte, MD, Ph.D. (1)
PMID 33477979, PMID 33989559, PMID 36094839, PMID 36821617, PMID 37875144, PMID 38252908, PMID 40178841, PMID 41062829, PMID 42476727, PMID 42558795
2023 (4), 2019 (1), P50CA254865 (1)